Searchable abstracts of presentations at key conferences in endocrinology

ea0065op6.1 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

Extended TSS (guided by 11C-methionine PET + MRI (Met-PET/MRCR)) can be an effective treatment option for patients with persistent acromegaly due to previously deemed unresectable lateral disease

Bashari Waiel A , Senanayake Russell , Fernandez-Pombo Antia , Gillett Daniel , Koulouri Olympia , Powlson Andrew , Cheow Heok , Mendichovszky Iosif , Kolias Angelos , Tysome James , Santarius Thomas , Mannion Richard , Gurnell Mark

Objective: To determine if an extended lateral approach to trans-sphenoidal surgery (TSS), guided by 11C-Methionine PET/CT co-registered with volumetric MRI (Met-PET/MRCR), can lead to remission in patients with persistent acromegaly due to post-operative lateral/para-sellar tumour remnants.Methods: We identified eight patients with persistent acromegaly following primary intervention [TSS ± medical therapy ± radiotherapy ...

ea0077p212 | Neuroendocrinology and Pituitary | SFEBES2021

Cabergoline treatment in human primary non-functioning pituitary adenomas

Begalli Federica , Komagata Tatsuya , Suleyman Oniz , Magid Kesson , Rice Thomas , Collier David , Dorward Neil , Grieve Joan , Mendoza Nigel , Nair Ramesh , Kolias Angelos , Khan Danyal , Marcus Hani J , Botta Joaquin , McCormick Peter J , Shinozaki Koji , Korbonits Marta

Non-functioning pituitary adenomas (NFPAs) are the second most common subtype (15-43%) of all clinically presenting pituitary adenomas. Although the primary treatment of symptomatic NFPAs is surgery, gross total resection is achieved only in about 66% of the cases, and 20% of gross total resected tumours recur after 10 years. Despite recent advances in medical management of pituitary tumours, NFPAs remain the only subtype with no widely accepted pharmacological treatment. Expr...

ea0094oc3.1 | Neuroendocrinology and Pituitary | SFEBES2023

CDC42: a potential therapeutic target of clinically non-functioning pituitary neuroendocrine tumours

Rai Ashutosh , Begalli Federica , Barry Sayka , Rice Thomas , Magid Kesson , Suleyman Oniz , Dorward Neil , Grieve Joan , Kolias Angelos , Khan Danyal , J Marcus Hani J. , Radotra Bishan D. , Chhabra Rajesh , Dhandapani S S. , Tripathi Manjul , Ahuja Chirag K. , Dutta Pinaki , Korbonits Marta

Background: There is no effective medical treatment available for non-functioning pituitary neuroendocrine tumours (NF-PitNETs). Recurrence (7-12%) or incomplete resection (30-45%) is a common feature. Thus, finding novel medical therapies to help the management of these tumours would be of great value. By using high-throughput mass spectrometry combined with functional characterisation, we explored novel therapeutic targets for NF-PitNETs.<p class="abstex...